CancerRisk+
AI-Powered Cancer Risk Assessment
AI-powered Genetic Test Combining Polygenic Risk Scores for Smarter Cancer Screening
85% of breast cancer cases occur in individuals with no family history
Only 5-10% of cancers are caused by single-gene mutations, yet traditional genetic tests focus solely on these mutations**.
CancerRisk+ incorporates polygenic risk scores (PRS), analyzing multiple genetic variants with AI to provide a more accurate and comprehensive cancer risk assessment. Unlike single-gene tests, PRS provides a broader and more precise cancer risk estimate by capturing the combined effect of multiple genetic factors.
What is CancerRisk+
CancerRisk+ is an AI-powered cancer risk assessment tool that integrates advanced PRS, equipping clinicians with precise, actionable screening strategies.
What It Covers:
- Breast cancer
- Colon cancer
- Prostate cancer
- Lung cancer
- Melanoma
- Ovarian cancer
Key Advantages of CancerRisk+
AI-powered insights
integrating polygenic risk
scores (PRS)
More accurate risk prediction
than using only single-gene testing
Seamless integration
into EMRs for real-time decision support
Actionable recommendations
for personalized screening and treatment
What Do Clinicians Say?
What Do Clinicians Say?
“This partnership perfectly aligns with our mission to provide the highest standard of concierge medicine. By integrating OpenDNA’s advanced genetic risk assessments into our practice, we offer patients unparalleled insights into their health, empowering them to make informed decisions for a longer, healthier life.”
Dr. Julia Gold, Founder and Lead Physician of Encore Concierge Medicine
Make Cancer Risk Assessment Smarter, Earlier, and More Accurate
References:
*Haber G, Ahmed NU, Pekovic V. Family history of cancer and its association with breast cancer risk perception and repeat mammography. Am J Public Health. 2012;102(12):2322–2329. doi:10.2105/AJPH.2012.300786.
**Ngeow J, Eng C. Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet. NPJ Genom Med. 2016;1:15006. doi:10.1038/npjgenmed.2015.6